Citations

Clear

3138 citation(s) found for "Smith, AM".

Presentation and outcomes of chronic rhinosinusitis following liver and kidney transplant
Spillinger, Aviv , Low, Christopher M. , Smith, Byron M., Stokken, Janalee K., O’Brien, Erin K. , O'Brien, Erin K , Choby, Garret

Mayo Clinic

World Journal of Otorhinolaryngology - Head and Neck Surgery | June 4, 2020 | Volume: 7 | Issue: 2 | Pages: 139-145

10.1016/j.wjorl.2020.05.001 | PMID 33997724 Get It

ObjectiveThis study aims to describe presenting characteristics of patients diagnosed with non‐invasive chronic rhinosinusitis (CRS) following liver or kidney transplant and determine factors associated with disease‐related complications, selection of endoscopic sinus surgery (ESS), and disease resolution in this population.Study designRetrospective chart review.SettingAn academic tertiary care center (Mayo Clinic, Rochester, Minnesota).Subjects and methodsLiver and kidney transplant recipients evaluated by Mayo Clinic otolaryngologists for CRS between 1998 and 2018 were identified. Univariate and multivariate logistic regression analyses were used to determine patient factors and treatment modalities associated with developing complications, selection of ESS, and disease resolution.ResultsFifty‐seven patients met inclusion criteria. No patients developed intraorbital or intracranial complications of their CRS. Multivariate modeling demonstrated that the presence of polyps (P = 0.036) was associated with undergoing ESS within one year of presentation. A higher Lund–Mackay (LM) computed tomography score (P = 0.023) and older age (P = 0.018) were significantly associated with decreased disease resolution. No other factors were significantly associated with the use of endoscopic sinus surgery within one year of otolaryngology presentation or resolution of CRS in this cohort.ConclusionThe risk of developing CRS‐related intraorbital or intracranial complications in this immunecompromised patient cohort may be lower than originally thought. For liver‐ and kidney‐recipients stable on immunosuppressive medication for many years, prognostic factors for CRS may mirror those for immunocompetent patients.
Geographic and socioeconomic considerations for glioblastoma treatment in the elderly at a national level: a US perspective
Lu, Victor M. , Lewis, Cole T. , Esquenazi, Yoshua

Mayo Clinic

Neuro-Oncology Practice | June 3, 2020 | Volume: 7 | Issue: 5 | Pages: 522-530

10.1093/nop/npaa029 | PMID 33014393 Get It

Abstract Background Treatment for glioblastoma (GBM) in elderly (age > 65 years) patients can be affected by multiple geographic and socioeconomic parameters. Correspondingly, the aim of this study was to determine trends in treatment of elderly GBM patients in the United States. Methods All GBM patients in the U.S. National Cancer Database between 2005 and 2016 were retrospectively reviewed. Status of treatment by triple therapy (resection, chemotherapy, and radiation) were summarized and analyzed by U.S. Census region. Results There were 44 338 GBM patients included, with 21 573 (49%) elderly and 22 765 (51%) nonelderly patients with median ages 72 years (range, 65-90 years) and 47 years (range, 40-64 years), respectively. Compared to nonelderly patients, elderly patients had significantly lower odds of being treated by triple therapy (odds ratio, OR = 0.54) as a whole, and its individual elements of resection (OR = 0.78), chemotherapy (OR = 0.46), radiation therapy (OR = 0.52). This was reflected in each U.S. Census region, with the lowest odds of being treated with triple therapy, surgical resection, chemotherapy, and radiation therapy in New England (OR = 0.51) Mountain (OR = 0.66), West North Central (OR = 0.38), and the Middle Atlantic (OR = 0.44), respectively. Multivariable analysis revealed multiple socioeconomic parameters that significantly predicted lower odds of triple therapy in the elderly. Conclusions In the United States alone, there exists geographic disparity in the treatment outcomes of elderly GBM patients. Multiple socioeconomic parameters can influence access to treatment modalities for elderly patients compared to younger patients in different geographic regions, and public health initiatives targeting these aspects may prove beneficial conceptually to optimize and homogenize clinical outcomes.
Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
Jitprapaikulsan, Jiraporn , Fryer, James P., Majed, Masoud , Jenkins, Sarah M. , Cabre, Philippe, Hinson, Shannon R., Weinshenker, Brian G. , Mandrekar, Jay , Chen, John J. , Lucchinetti, Claudia F. , Jiao, Yujuan , Segan, Jessica, Schmeling, John E., Mills, John R. , Pittock, Sean J. , Smith, Carin Y. , Weinshenker, Brian G , Pittock, S J , Chen, John J , Flanagan, Eoin P. , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | May 28, 2020 | Volume: 7 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000000727 | PMID 35413004 Get It

Middle-aged Woman With Optic Neuritis and a Rapidly Progressing Retinal Vaso-occlusive Disease
Starr, Matthew R. , Smith, Wendy M. , Garcia, Maria L, Starr, Matthew R , García, Maria Luisa

Mayo Clinic

JAMA Ophthalmology | May 28, 2020 | Volume: 138 | Issue: 7 | Pages: 797

10.1001/jamaophthalmol.2020.0605 | PMID 32463455 Get It

The Science Fiction of Medical Quackery: Ray Bradbury's “Skeleton”
Stone, Jon , Smith, Jonathan H.

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 27, 2020 | Volume: 60 | Issue: 9 | Pages: 2087-2088

10.1111/head.13852 | PMID 32459002 Get It

0719 The Association of Sleep Apnea and Cardiorespiratory Fitness with Long-Term Major Cardiovascular Events
Barillas-Lara, Maria Irene , Smith, J. Roy, Bonikowske, Amanda R. , Allison, Thomas G. , Olson, Thomas P. , Somers, Virend K., Caples, Sean M., Medina‐Inojosa, José R. , Kolla, Bhanu Prakash , López-Jiménez, Francisco , Mansukhani, Meghna P.

Mayo Clinic

Sleep | May 27, 2020 | Volume: 43 | Issue: Supplement_1 | Pages: A273-A274

10.1093/sleep/zsaa056.715 Get It

Abstract Introduction Sleep disordered breathing (SDB) is associated with adverse cardiovascular outcomes and decreased cardiorespiratory fitness (CRF). The risk of long-term major adverse cardiovascular events (MACE) when SDB and decreased CRF co-occur has not been determined. Methods We included consecutive patients that underwent a symptom-limited cardiopulmonary exercise test followed by first-time diagnostic polysomnography within 6 months. Patients were stratified based on the presence of moderate-severe SDB (apnea/hypopnea index ≥15/hour) and decreased CRF defined as <70% predicted peak oxygen consumption (VO2). MACE was a composite outcome of myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), stroke/transient ischemic attack (TIA) and death. Cox-proportional hazard models adjusting for factors known to influence CRF and MACE were constructed. Results Of 498 included patients (60±13 years, 28.1% female), 175 (35%) had MACE (MI=17, PCI=14, CABG=13, stroke=20, TIA=12, deaths=99) at a median follow-up of 8.7 years (interquartile range=6.5-10.3 years). After adjusting for age, sex, beta-blockers, systemic hypertension, diabetes mellitus, coronary artery disease, cardiac arrhythmia, chronic obstructive pulmonary disease, smoking and positive airway pressure (PAP) usage, decreased CRF alone (HR=1.91, 95%CI=1.15-3.18, p=0.012), but not SDB alone (HR=1.26, 95%CI=0.75-2.13, p=0.389) was associated with increased risk of MACE. Those with SDB and decreased CRF had increased risk of MACE compared to patients with decreased CRF alone (HR=1.85, 95%CI=1.21-2.84, p<0.005) after accounting for these confounders; the risk was attenuated after additionally adjusting for adequate adherence to PAP (HR=1.85, 95%CI=0.99-3.05, p=0.05). Conclusion The incidence of MACE, including mortality, was high in this sample. Moderate-severe SDB with concurrent decreased CRF was associated with higher risk of MACE than decreased CRF alone. These results highlight the importance of including CRF in the risk assessment of patients with SDB, and conversely, that of screening for SDB in patients with low peak VO2. Support None.
Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816
Ha, Chul S. , Pinnix, Chelsea C. , Bartlett, Nancy L. , Evens, Andrew M. , Knopp, Michael V. , Leonard, John P. , Smith, Sonali M. , Friedberg, Jonathan W. , Zhang, Jun , Pinnix, Chelsea C , Bartlett, Nancy L , Rimsza, Lisa, Evens, Andrew M , LeBlanc, Michael , Schöder, Heiko , Hsi, Eric D. , Rimsza, Lisa M. , Zhang, Jun , Kahl, Brad S. , Li, Hongli , Constine, Louis S

Mayo Clinic

Leukemia & Lymphoma | May 26, 2020 | Volume: 61 | Issue: 10 | Pages: 2442-2447

10.1080/10428194.2020.1768388 | PMID 32452714 Get It

Nasal vestibulitis: An MNCCTN natural history trial—Nasal vestibulitis symptoms associated with paclitaxel, docetaxel, and other chemotherapy agents.
Zahrieh, David , Smith, Deanne s., Young, Susan E. , Wolfe, Eric, Thomé, Stephan D. , Register, Terra, Piens, Jill, McCue, Shaylene , Loprinzi, Charles L. , Cathcart-Rake, Elizabeth , Young, Susan, O'Connor, Amanda, Lacouture, Mario E.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e24086-e24086

10.1200/jco.2020.38.15_suppl.e24086 Get It

e24086 Background: Nasal vestibulitis has been infrequently described as a side effect of cancer-directed therapy; however, a preliminary study reported that 71% of patients undergoing taxane chemotherapy experienced nasal vestibulitis symptoms. This natural history trial describes the incidence, characteristics, and severity of nasal vestibulitis symptoms among patients undergoing paclitaxel, docetaxel, and non-taxane chemotherapy. Methods: Eligible participants who reported baseline (prior to starting chemotherapy) nasal symptoms ≤ 2 on a 10-point scale were enrolled in this trial upon initiation of a new treatment regimen, involving paclitaxel or docetaxel, or non-taxane chemotherapy. Participants completed nasal symptom logs each time they received a dose of therapy until either the regimen was stopped or four months had passed. The proportion of patients reporting new nasal symptoms was estimated within each cohort with the 95% exact confidence interval (CI). A cumulative incidence model was utilized to quantify the incidence of treatment-emergent nasal symptoms within each cohort, while controlling for age, sex, smoking history, and history of asthma or allergies. Results: Thirty-five participants received paclitaxel, 21 received docetaxel, and 25 received other types of chemotherapy. 86.4% of participants were female, mean age was 60.2 ± 11.2 years; 93.8% of participants completed 2 or more surveys. A higher percentage of participants in the paclitaxel cohort experienced new nasal vestibulitis symptoms than participants in the other two cohorts. The percentage (95% CI) of participants with nasal symptoms, for patients receiving paclitaxel, docetaxel, and non-taxane chemotherapy were 74.3% (56.7%, 87.5%), 47.6% (25.7%, 70.2%), and 44.0% (24.4%, 65.1%), respectively. Epistaxis was reported by 60% of participants in the paclitaxel cohort. Paclitaxel-receiving participants also reported nasal dryness (48.6%), scabbing (40.0%), and pain (20.0%). Nearly half of participants reported moderate symptoms (4-7 out of a 10-point scale), with 8.6% reporting symptoms as severe (8-10 on a 10-point scale). Conclusions: Nasal vestibulitis is a common side effect of chemotherapy, especially paclitaxel chemotherapy.
Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.
Ruppert, Amy S. , Mandrekar, Sumithra J. , Booth, Allison M., Brander, Danielle M. , Brown, Jennifer R. , Nattam, Sreenivasa, Litzow, Mark R. , Owen, Carolyn , Kuzma, Charles, Little, Richard F. , Smith, Scott E. , Stone, Richard M. , Byrd, John C. , Woyach, Jennifer A. , Ding, Wei , Bartlett, Nancy L. , Coutré, Steven , Larson, Richard A. , Erba, Harry Paul , Abramson, Jeremy S.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e20004-e20004

10.1200/jco.2020.38.15_suppl.e20004 Get It

e20004 Background: IB is a Bruton’s tyrosine kinase inhibitor that showed superior progression-free survival compared with BR in CLL patients (pts) 65 years or older in a randomized phase 3 trial (Woyach et al, NEJM 2018). Pts receiving IB had higher rates of atrial fibrillation (AFIB) and hypertension (HTN); BR pts had higher rates of hematologic toxicity. Differences in treatment duration for BR (6 cycles) and IB (until progression) complicated adverse event (AE) comparisons. Here we use an exploratory approach to compare toxicity burden between arms and provide assessment of AFIB, HTN and infections (INF). Methods: AEs were reported for each of cycles 1-6 and then every 3 cycles until progression or nonprotocol CLL therapy. Only grade (gr) 3-4 AEs were reported thereafter until death. A simple global AE score was calculated for each pt by summing grades of all gr 1-4 AEs and dividing by the number of cycles over which AEs were submitted. Results: 537 pts began therapy (176 BR, 361 IB). 68% on BR completed all 6 cycles. At a median follow-up of 38 months, 64% remained on IB. Treatment discontinuation for AE occurred in 10% and 14% of BR and IB pts. Overall, median AE score was 1.8 (interquartile range (IQR) 0.9-3.3) and 3.8 (IQR 2.3-5.9) in BR and IB arms (p < 0.01). For cycles 1-6, median AE score was 6.2 (IQR 3.8-9.0) and 4.8 (IQR 3.0-7.2) in BR and IB arms (p < 0.01). In the IB arm, median AE score post 6 cycles decreased significantly to 3.4 (IQR 1.9-5.6) (p < 0.01). Gr 3 or higher cumulative rates of AFIB, HTN, and INF over time appear in the table. 100 pts (26/176 BR, 74/361 IB) had 137 severe INF (39% respiratory: 16 BR, 37 IB; 25% skin: 3 BR, 31 IB; 12% GU: 3 BR, 13 IB; 25% other: 12 BR, 22 IB). There were 7 gr 5 INF (3 BR, 4 IB), none confirmed fungal. Conclusions: There was no difference in treatment discontinuation rates for AE. Overall toxicity burden was significantly higher for IB, although IB toxicity burden decreased after 6 cycles. Toxicity burden was significantly higher in cycles 1-6 for pts receiving BR. Risk of severe AFIB, HTN, and INF is highest in the first year of IB. A simple AE score provides valuable information, especially when evaluating regimens of varying length. Clinical trial information: NCT01886872 . Support: U10CA180821, U10CA180882, U24CA196171; https://acknowledgments.alliancefound.org ; Pharmacyclics; ClinicalTrials.gov Identifier: NCT01886872. [Table: see text]